Julie Parsons, MD

Professor of clinical pediatrics and neurology; Haberfeld Family Endowed Chair in Pediatric Neuromuscular Disorders, Children’s Hospital Colorado

Articles

Using Small Molecule Treatment for SMA Management

July 17, 2021

Experts in pediatric neurology share insights on the role of small molecule treatment for SMA through the recent FDA approval of risdiplam and discuss factors to consider when tailoring therapy for individual patients.

Targeted Therapies for SMA Management: Nusinersen

June 29, 2021

John Brandsema, MD, and Julie Parsons, MD, discuss the approval of nusinersen for the treatment of spinal muscular atrophy and their personal experiences regarding drug safety and administration in patients.